Skip to main content
. 2020 Feb 22;111(4):1291–1302. doi: 10.1111/cas.14332

Figure 3.

Figure 3

Immunohistochemical staining scores for phosphorylated mammalian target of rapamycin (p‐mTOR) (A) and phosphorylated S6 ribosomal protein (p‐S6) (B) in cohort 1 (patients with low rectal cancer treated with neoadjuvant chemoradiotherapy; left) and cohort 2 (patients with colorectal cancer not treated with neoadjuvant therapy; right). Horizontal lines represent the median expression scores of p‐mTOR (A, score of 6) and p‐S6 (B, score of 3) in cohort 2